Additional blood pressure screening may reduce incidence of CVD events and death by up to 3 percent

April 22, 2012

A 25 per cent increase in high blood pressure screening in 19 developing countries would reduce the number of cardiovascular disease (CVD) events and deaths that occur each year by up to 3 per cent in these countries. The preliminary data presented today at the World Congress of Cardiology are the first findings from a new report from Harvard that will be published later this year.

The study found that around 900 million people in developing countries have but that only one-third are aware of their disease. Moreover, only 100 million of these people receive treatment, while only 5 per cent of the total are controlled.

Against this backdrop, this study was designed to assess the cost-effectiveness of an intervention to increase screening by 25 per cent in developing countries using a non-lab screening tool to treat those with a of greater than 140 mmHg and CVD risk of greater than 20 per cent.

The study found that screening an additional 25 per cent of the population would lead to an increase of more than 10 per cent in the rate of appropriate in high-risk individuals. The intervention would lead to about a 1-3 per cent reduction in CVD events and deaths. Furthermore, the incremental cost-effectiveness ratios of these screening programs were found to be well below one times GDP per capita in the 19 developing countries assessed.

"Strategies to increase the screening for could lead to significant reductions in CVD deaths, at costs that are considered to be acceptable according to WHO recommendations," said Dr. Thomas Gaziano, assistant professor, Harvard School of Medicine.

Explore further: Age alone should be used to screen for heart attacks and strokes, say experts

Related Stories

Recommended for you

No new heart muscle cells in mice after the newborn period

November 5, 2015

A new study from Sweden's Karolinska Institutet shows that new heart muscle cells in mice are mainly formed directly after birth. After the neonatal period the number of heart muscle cells does not change, and A new study ...

Nanotechnology could spur new heart treatment

October 29, 2015

A new nanoparticle developed by University of Michigan researchers could be the key to a targeted therapy for cardiac arrhythmia, a condition that causes the heart to beat erratically and can lead to heart attack and stroke.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.